|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: YIPF6 |
Gene summary for YIPF6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | YIPF6 | Gene ID | 286451 |
| Gene name | Yip1 domain family member 6 | |
| Gene Alias | FinGER6 | |
| Cytomap | Xq12-q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0002064 | UniProtAcc | Q96EC8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 286451 | YIPF6 | LZE4T | Human | Esophagus | ESCC | 1.87e-15 | 4.81e-01 | 0.0811 |
| 286451 | YIPF6 | LZE7T | Human | Esophagus | ESCC | 2.80e-09 | 6.48e-01 | 0.0667 |
| 286451 | YIPF6 | LZE8T | Human | Esophagus | ESCC | 3.53e-07 | 2.20e-01 | 0.067 |
| 286451 | YIPF6 | LZE20T | Human | Esophagus | ESCC | 1.55e-07 | 2.92e-01 | 0.0662 |
| 286451 | YIPF6 | LZE22T | Human | Esophagus | ESCC | 1.38e-03 | 3.39e-01 | 0.068 |
| 286451 | YIPF6 | LZE24T | Human | Esophagus | ESCC | 4.17e-33 | 8.62e-01 | 0.0596 |
| 286451 | YIPF6 | LZE6T | Human | Esophagus | ESCC | 3.08e-04 | 3.11e-01 | 0.0845 |
| 286451 | YIPF6 | P1T-E | Human | Esophagus | ESCC | 7.84e-04 | 4.58e-01 | 0.0875 |
| 286451 | YIPF6 | P2T-E | Human | Esophagus | ESCC | 3.44e-23 | 4.92e-01 | 0.1177 |
| 286451 | YIPF6 | P4T-E | Human | Esophagus | ESCC | 5.59e-36 | 7.80e-01 | 0.1323 |
| 286451 | YIPF6 | P5T-E | Human | Esophagus | ESCC | 1.78e-20 | 4.45e-01 | 0.1327 |
| 286451 | YIPF6 | P8T-E | Human | Esophagus | ESCC | 3.07e-46 | 8.40e-01 | 0.0889 |
| 286451 | YIPF6 | P9T-E | Human | Esophagus | ESCC | 7.69e-17 | 3.31e-01 | 0.1131 |
| 286451 | YIPF6 | P10T-E | Human | Esophagus | ESCC | 2.17e-22 | 3.50e-01 | 0.116 |
| 286451 | YIPF6 | P11T-E | Human | Esophagus | ESCC | 1.24e-16 | 5.47e-01 | 0.1426 |
| 286451 | YIPF6 | P12T-E | Human | Esophagus | ESCC | 1.10e-45 | 8.22e-01 | 0.1122 |
| 286451 | YIPF6 | P15T-E | Human | Esophagus | ESCC | 1.69e-46 | 8.77e-01 | 0.1149 |
| 286451 | YIPF6 | P16T-E | Human | Esophagus | ESCC | 3.64e-41 | 7.81e-01 | 0.1153 |
| 286451 | YIPF6 | P17T-E | Human | Esophagus | ESCC | 2.76e-04 | 2.32e-01 | 0.1278 |
| 286451 | YIPF6 | P19T-E | Human | Esophagus | ESCC | 2.37e-08 | 4.97e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
| GO:00605763 | Esophagus | ESCC | intestinal epithelial cell development | 12/8552 | 14/18723 | 2.51e-03 | 1.08e-02 | 12 |
| GO:0002066 | Esophagus | ESCC | columnar/cuboidal epithelial cell development | 29/8552 | 44/18723 | 5.41e-03 | 2.02e-02 | 29 |
| GO:000206412 | Liver | Cirrhotic | epithelial cell development | 80/4634 | 220/18723 | 7.63e-05 | 8.44e-04 | 80 |
| GO:000206422 | Liver | HCC | epithelial cell development | 114/7958 | 220/18723 | 3.19e-03 | 1.47e-02 | 114 |
| GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
| GO:00605762 | Oral cavity | OSCC | intestinal epithelial cell development | 10/7305 | 14/18723 | 1.44e-02 | 4.69e-02 | 10 |
| GO:000206417 | Prostate | BPH | epithelial cell development | 85/3107 | 220/18723 | 3.16e-15 | 4.55e-13 | 85 |
| GO:0060576 | Prostate | BPH | intestinal epithelial cell development | 8/3107 | 14/18723 | 6.63e-04 | 4.46e-03 | 8 |
| GO:0060575 | Prostate | BPH | intestinal epithelial cell differentiation | 9/3107 | 23/18723 | 8.32e-03 | 3.60e-02 | 9 |
| GO:000206418 | Prostate | Tumor | epithelial cell development | 88/3246 | 220/18723 | 1.30e-15 | 2.38e-13 | 88 |
| GO:00605761 | Prostate | Tumor | intestinal epithelial cell development | 8/3246 | 14/18723 | 8.99e-04 | 5.96e-03 | 8 |
| GO:00605751 | Prostate | Tumor | intestinal epithelial cell differentiation | 9/3246 | 23/18723 | 1.11e-02 | 4.56e-02 | 9 |
| GO:000206427 | Thyroid | HT | epithelial cell development | 35/1272 | 220/18723 | 2.12e-06 | 7.61e-05 | 35 |
| GO:00605764 | Thyroid | HT | intestinal epithelial cell development | 6/1272 | 14/18723 | 1.82e-04 | 2.68e-03 | 6 |
| GO:00605752 | Thyroid | HT | intestinal epithelial cell differentiation | 7/1272 | 23/18723 | 6.13e-04 | 7.07e-03 | 7 |
| GO:00020651 | Thyroid | HT | columnar/cuboidal epithelial cell differentiation | 14/1272 | 91/18723 | 3.23e-03 | 2.55e-02 | 14 |
| GO:00020661 | Thyroid | HT | columnar/cuboidal epithelial cell development | 8/1272 | 44/18723 | 8.78e-03 | 4.95e-02 | 8 |
| GO:0002064112 | Thyroid | PTC | epithelial cell development | 101/5968 | 220/18723 | 8.53e-06 | 9.74e-05 | 101 |
| GO:000206428 | Thyroid | ATC | epithelial cell development | 103/6293 | 220/18723 | 3.06e-05 | 2.55e-04 | 103 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| YIPF6 | SNV | Missense_Mutation | novel | c.28N>A | p.Asp10Asn | p.D10N | Q96EC8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.027) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| YIPF6 | SNV | Missense_Mutation | c.445N>G | p.Gln149Glu | p.Q149E | Q96EC8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| YIPF6 | SNV | Missense_Mutation | c.596N>T | p.Ser199Phe | p.S199F | Q96EC8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| YIPF6 | SNV | Missense_Mutation | rs763487554 | c.176N>A | p.Arg59His | p.R59H | Q96EC8 | protein_coding | tolerated(0.06) | possibly_damaging(0.489) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| YIPF6 | SNV | Missense_Mutation | novel | c.312N>T | p.Met104Ile | p.M104I | Q96EC8 | protein_coding | tolerated(0.36) | benign(0.017) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| YIPF6 | SNV | Missense_Mutation | novel | c.100N>A | p.Val34Ile | p.V34I | Q96EC8 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| YIPF6 | SNV | Missense_Mutation | novel | c.301N>G | p.Leu101Val | p.L101V | Q96EC8 | protein_coding | tolerated(0.13) | possibly_damaging(0.838) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| YIPF6 | SNV | Missense_Mutation | novel | c.313C>A | p.Leu105Met | p.L105M | Q96EC8 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| YIPF6 | SNV | Missense_Mutation | novel | c.133N>T | p.Arg45Cys | p.R45C | Q96EC8 | protein_coding | deleterious(0.05) | benign(0.145) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| YIPF6 | SNV | Missense_Mutation | c.289N>A | p.Leu97Ile | p.L97I | Q96EC8 | protein_coding | tolerated(0.17) | possibly_damaging(0.679) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |